A new publication involving cagrilintide was released on August 17, 2026. The paper, titled "Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials," appeared in Naunyn-Schmiedeberg's Archives of Pharmacology.
The publication is described as a systematic review and GRADE-assessed meta-analysis of randomized controlled trials involving cagrisema, a combination that includes cagrilintide. No specific findings, effect sizes, or conclusions from the review are included in the available event data.
Cagrilintide remains classified as an unapproved compound under research status. This means it has not received regulatory approval for clinical use outside of study settings. The publication represents an academic contribution to the literature rather than a regulatory or clinical milestone.
Readers interested in the broader context of cagrilintide, including its research background and development status, can consult the compound overview for additional information.